Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 599626

Drug Profile

BMS 599626

Alternative Names: AC480; BMS599626

Latest Information Update: 23 Jul 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Ambit Biosciences Corporation; Bristol-Myers Squibb
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Glioma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 23 Jul 2015 Discontinued - Phase-I for Breast cancer, Glioma, Non-small cell lung cancer and Solid tumours (Combination therapy) in USA after October 2013 (IV)
  • 22 Jun 2015 Ambit Biosciences withdraws phase-I trial in Solid tumours in USA prior to enrolment (Combination therapy) (NCT01245543)
  • 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top